



Metoprolol Therapy and *CYP2D6* Genotype

Laura Dean, MD¹

Created: April 4, 2017.

Introduction

Metoprolol is a beta blocker used in the treatment of hypertension, angina, and heart failure. Metoprolol selectively blocks beta₁ adrenoreceptors mainly expressed in cardiac tissue. Blockade of these receptors reduces the heart rate and decreases the force of heart contractions.

Metoprolol is primarily metabolized by the *CYP2D6* enzyme. Approximately 8% of Caucasians and 2% of most other populations have absent *CYP2D6* activity and are known as “*CYP2D6* poor metabolizers.” In addition, a number of drugs inhibit *CYP2D6* activity, such as quinidine, fluoxetine, paroxetine, and propafenone.

The FDA-approved drug label for metoprolol states that *CYP2D6* poor metabolizers, and normal metabolizers who concomitantly take drugs that inhibit *CYP2D6*, will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity (1).

The Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Association for the Advancement of Pharmacy (KNMP) has published metoprolol dosing recommendations based on *CYP2D6* genotype. For individuals who have a *CYP2D6* gene variation that reduces the conversion of metoprolol to inactive metabolites, DPWG states that the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia. For *CYP2D6* poor metabolizers, if a gradual reduction in heart rate is desired, or in the event of symptomatic bradycardia, DPWG recommends increasing the dose of metoprolol in smaller steps and/or prescribing no more than 25% of the standard dose. For other cases, no action is required (2).

Please note: Beta blockers such as metoprolol have been demonstrated in several large trials to be safe and effective for treatment of patients with cardiovascular disease. As a mainstay of therapy associated with improvements in quality of life, hospitalization rates, and survival (3, 4), clinical care pathways that might lead to underutilization of beta blockers require scrutiny. FDA points out that *CYP2D6* poor metabolizers will have decreased cardioselectivity for metoprolol due to increased metoprolol blood levels. Yet, it is common clinical practice to adjust the dose of metoprolol according to the patient's heart rate. FDA does not specifically comment on the role of genetic testing for initiating therapy.

Drug: Metoprolol

Metoprolol is a commonly prescribed drug that belongs to the drug class of beta-adrenoreceptor antagonists, also known as “beta blockers.” Metoprolol is indicated to treat hypertension, angina, and heart failure (stable, symptomatic (NYHA Class II or III) heart failure). Metoprolol selectively blocks the beta₁ adrenoreceptor (1).

There are two main types of adrenoreceptors, alpha and beta, each of which have numbered subtypes. The beta adrenoreceptors have three subtypes, beta₁, beta₂, and beta₃. All three subtypes are coupled to the G_s protein, which in turn activates adenylate cyclase enzyme, which catalyzes the production of cyclic AMP (cAMP).

The binding of an agonist, such as the catecholamines adrenaline and noradrenaline, to beta receptors leads to a rise in the intracellular concentration of cAMP, which triggers signaling pathways. Stimulation of the beta₁ receptor, which is predominantly expressed in cardiac tissue, leads to an increase in heart rate and an increase in the contractility of the atria and ventricles. It also leads to the increased secretion of hormones from other tissues—renin (from the kidneys), ghrelin (from the stomach), and amylase (from the salivary glands).

In the treatment of heart failure, beta blockers such as extended-release metoprolol are thought to protect the heart from increased catecholamine stimulation. In the short term, adrenergic activation can help the heart maintain cardiac performance, but over time, continued activation can be detrimental. Harmful effects include a persistently increased heart rate, down-regulation and impaired functioning of the beta receptors, and myocyte hypertrophy and death—which leads to adverse remodeling of heart tissue (5, 6).

Metoprolol exerts its therapeutic effects by reducing the impact of catecholamine stimulation. Metoprolol reduces the heart rate, improves contractile function by stimulating the upregulation of beta-1 receptors, reduces vasoconstriction, and possibly also reduces the risk of arrhythmias (3, 5, 7, 8).

Metoprolol is a racemic mixture of R- and S-enantiomers (an equal amount of left- and right-handed enantiomers, which are molecules that are mirror images of each other, but are not superimposable on one another).

Metoprolol is primarily metabolized by CYP2D6, an enzyme which is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations. Individuals who lack CYP2D6 activity will have higher plasma concentrations of metoprolol, almost 5-fold higher, and may be at an increased risk of side effects (9-12).

In addition, at higher plasma concentrations, metoprolol is less cardio-selective. Metoprolol can inhibit beta₂ receptors, which are mainly located in the bronchial and vascular musculature.

Genetic variants of the *CYP2D6* gene have been found to influence the ratio of enantiomers, the dose and dose titration of metoprolol, and to influence heart rate—CYP2D6 poor metabolizers have an increased risk of bradycardia (13-16). However, *CYP2D6* does not appear to influence the efficacy of metoprolol when used to treat hypertension (17).

Variants within the beta₁ receptor have also been found to influence the treatment response to specific beta blockers. The most commonly studied is a reduced function variant, Arg389Gly, which leads to reduced levels of cAMP and diminished beta₁ receptor signaling cascades (18). Individuals who are homozygous Arg389 carriers may have a more favorable response to metoprolol treatment than individuals who are homozygous for Gly389 (18-21).

The Cytochrome P450 Superfamily

The cytochrome P450 superfamily (CYP450) is a large and diverse group of enzymes that form the major system for metabolizing lipids, hormones, toxins, and drugs. The *CYP450* genes are very polymorphic and can result in reduced, absent, or increased enzyme activity.

Gene: *CYP2D6*

CYP2D6 is highly polymorphic, with over 100 star (*) alleles described (22). *CYP2D6**1 is the reference (or wild-type) allele encoding enzyme with normal activity. The *CYP2D6**2, *33, and *35 alleles are also considered to confer normal activity (Table 1).

Table 1. Activity status of selected CYP2D6 alleles

Allele type	CYP2D6 Alleles
Normal function	*1, *2, *33, *35
Decreased function	*9, *10, *17, *29, *36, *41
No function	*3-*8, *11-*16, *19-*21, *38, *40, *42

For a detailed list of CYP2D6 alleles, please see (22).

Individuals who have more than two normal function copies of the CYP2D6 gene are “ultrarapid metabolizers,” whereas individuals who carry two normal or one normal and one decreased function allele are classified as “normal metabolizers.”

Individuals with one normal and one no function allele or two decreased function alleles are categorized as “normal metabolizers” by recent nomenclature guidelines (23), but have also been categorized as “intermediate metabolizers” in the literature. Subjects with one decreased and one no function allele are predicted to be intermediate metabolizers and those with two no function alleles, poor metabolizers.

The most common no function alleles include CYP2D6*3, *4, *5, and *6 (24-27), and the most common decreased function alleles include CYP2D6*9, *10, *17, *29 and *41 (28-32) (Table 1).

There are large inter-ethnic differences in the frequency of these alleles. For example, CYP2D6*4 is the most common no function allele in Caucasians, but is less abundant in subjects with African ancestry, and is rare in Asians. In contrast, the decreased function allele CYP2D6*10 is the most common allele in Asians, and CYP2D6*17 is almost exclusively found in individuals with African ancestry (33).

Consequently, the phenotype frequencies also vary substantially among the major ethnicities and may vary among populations. Approximately 6-8% of European Caucasians and their descendants are poor metabolizers, mainly due to the prevalent no function CYP2D6*4 and *5 alleles (34, 35).

Genetic Testing

The NIH’s Genetic Testing Registry provides examples of the genetic tests that are currently available for metoprolol response and the CYP2D6 gene.

Results are typically reported as a diplotype, such as CYP2D6 *1/*1. A result for copy number, if available, is also important when interpreting CYP2D6 results (36).

Therapeutic Recommendations based on Genotype

This section contains excerpted¹ information on gene-based dosing recommendations. Neither this section nor other parts of this review contain the complete recommendations from the sources.

2016 Statement from the US Food and Drug Administration (FDA): Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations. CYP2D6 can be inhibited by a number of drugs. Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol’s cardioselectivity.

Please review the complete therapeutic recommendations that are located here: (1).

¹ The FDA labels specific drug formulations. We have substituted the generic names for any drug labels in this excerpt. The FDA may not have labeled all formulations containing the generic drug.

2016 Summary of recommendations from the Pharmacogenetics Working Group of the Royal Dutch Association for the Advancement of Pharmacy (KNMP):

CYP2D6 Poor Metabolizers:

The gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia.

Recommendation:

If a gradual reduction in heart rate is desired, or in the event of symptomatic bradycardia:

- 1 Increase the dose in smaller steps and/or prescribe no more than 25% of the standard dose

Other cases:

- 1 No action required

CYP2D6 Intermediate Metabolizers:

The gene variation reduces the conversion of metoprolol to inactive metabolites. However, the clinical consequences are limited mainly to the occurrence of asymptomatic bradycardia.

Recommendation:

If a gradual reduction in heart rate is desired, or in the event of symptomatic bradycardia:

- 1 Increase the dose in smaller steps and/or prescribe no more than 50% of the standard dose

Other cases:

- 1 No action required

CYP2D6 Ultrarapid Metabolizers:

The gene variation increases the conversion of metoprolol to inactive metabolites. This can increase the dose requirement. However, with a target dose of 200 mg/day, there was no effect on the blood pressure and hardly any effect on the reduction of the heart rate.

Recommendation:

1. Use the maximum dose for the relevant indication as a target dose
2. If the effectiveness is still insufficient: increase the dose based on effectiveness and side effects to 2.5 times the standard dose or select an alternative

Possible alternatives include:

- Heart failure: bisoprolol or carvedilol. Bisoprolol: advantage: not metabolised by CYP2D6; disadvantage: elimination depends on the kidney function. Carvedilol: advantage: elimination does not depend on the kidney function; disadvantage: is metabolised (to a lesser extent than metoprolol) by CYP2D6.
- Other indications: atenolol or bisoprolol. Neither is metabolised by CYP2D6.

Please review the complete therapeutic recommendations that are located here: (2)

Nomenclature of selected CYP2D6 alleles

Common allele name	Alternative names	HGVS reference sequence		dbSNP reference identifier for allele location
		Coding	Protein	
CYP2D6*4	1846G>A	NM_000106.5:c.506-1G>A	Variant occurs in a non-coding region (splice variant causes a frameshift)	rs3892097
CYP2D6*5	Variant results in a whole gene deletion			
CYP2D6*6	1707 del T Trp152Gly CYP2D6T	NM_000106.5:c.454delT	NP_000097.3:p.Trp152Glyfs	rs5030655
CYP2D6*10	100C>T (Pro34Ser)	NM_000106.5:c.100C>T	NP_000097.3:p.Pro34Ser	rs1065852
CYP2D6*17	1023C>T ^[1] (Thr107Ile)	NM_000106.5:c.320C>T	NP_000097.3:p.Thr107Ile	rs28371706
	2850C>T ^[2] (Cys296Arg)	NM_000106.5:c.886T>C	NP_000097.3:p.Cys296Arg	rs16947
CYP2D6*41	2850C>T ^[2] (Cys296Arg)	NM_000106.5:c.886T>C	NP_000097.3:p.Cys296Arg	rs16947
	2988G>A	NM_000106.5:c.985+39 G>A	Variant occurs in a non-coding region (impacts slicing).	rs28371725

^[1] In the literature, 1023C>T is also referred to as 1111C>T, and 2850C>T is also referred to 2938C>T.

^[2] In the literature, 2850C>T is also referred to as 2938C>T.

Guidelines for the description and nomenclature of gene variations are available from the Human Genome Variation Society (HGVS): <http://www.hgvs.org/content/guidelines>

Nomenclature for Cytochrome P450 enzymes is available from the Human Cytochrome P450 (CYP) Allele Nomenclature Database: <http://www.cypalleles.ki.se/>

Acknowledgments

The author would like to thank Larisa H. Cavallari, Pharm.D., Associate Professor, Department of Pharmacotherapy and Translational Research & Director, Center for Pharmacogenomics, University of Florida; Mandy van Rhenen, secretary of the Dutch Pharmacogenetics Working Group (DPWG), Centre for Information on Medicines, Royal Dutch Pharmacists Association (KNMP); and John Wikstrand, Professor of Clinical Physiology, Wallenberg Laboratory, University of Gothenburg, Sweden, for reviewing this summary.

References

1. TOPROL XL- metoprolol succinate tablet, extended release [Package insert]. Wilmington, DE: AstraZeneca; 2016. Available from: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a5762c6-d7a2-4e4c-10b7-8832b36fa5f4>
2. Royal Dutch Pharmacists Association (KNMP). Dutch Pharmacogenetics Working Group (DPWG). Pharmacogenetic Guidelines [Internet]. Netherlands. Metoprolol – CYP2D6 [Cited March 2017]. Available from: <http://kennisbank.knmp.nl/> [Access is restricted to KNMP membership.]
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*. 1999;353(9169):2001–7. PubMed PMID: 10376614.
4. Kotecha D., Manzano L., Krum H., Rosano G., et al. Effect of age and sex on efficacy and tolerability of beta blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. *BMJ*. 2016;353:i1855. PubMed PMID: 27098105.

5. Bristow M.R. beta-adrenergic receptor blockade in chronic heart failure. *Circulation*. 2000;101(5):558–69. PubMed PMID: 10662755.
6. Sackner-Bernstein J.D., Mancini D.M. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. *JAMA*. 1995;274(18):1462–7. PubMed PMID: 7474194.
7. Yoshikawa T., Handa S., Anzai T., Nishimura H., et al. Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. *Am Heart J*. 1996;131(2):329–36. PubMed PMID: 8579029.
8. Gilbert E.M., Abraham W.T., Olsen S., Hattler B., et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. *Circulation*. 1996;94(11):2817–25. PubMed PMID: 8941107.
9. Rau T., Wuttke H., Michels L.M., Werner U., et al. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. *Clin Pharmacol Ther*. 2009;85(3):269–72. PubMed PMID: 19037197.
10. Blake C.M., Kharasch E.D., Schwab M., Nagele P. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. *Clin Pharmacol Ther*. 2013;94(3):394–9. PubMed PMID: 23665868.
11. Jin S.K., Chung H.J., Chung M.W., Kim J.I., et al. Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers. *J Clin Pharm Ther*. 2008;33(5):567–73. PubMed PMID: 18834373.
12. Wuttke H., Rau T., Heide R., Bergmann K., et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. *Clin Pharmacol Ther*. 2002;72(4):429–37. PubMed PMID: 12386645.
13. Baudhuin L.M., Miller W.L., Train L., Bryant S., et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. *Am J Cardiol*. 2010;106(3):402–8. PubMed PMID: 20643254.
14. Batty J.A., Hall A.S., White H.L., Wikstrand J., et al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy. *Clin Pharmacol Ther*. 2014;95(3):321–30. PubMed PMID: 24193112.
15. Hamadeh I.S., Langaee T.Y., Dwivedi R., Garcia S., et al. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate. *Clin Pharmacol Ther*. 2014;96(2):175–81. PubMed PMID: 24637943.
16. Bijl M.J., Visser L.E., van Schaik R.H., Kors J.A., et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. *Clin Pharmacol Ther*. 2009;85(1):45–50. PubMed PMID: 18784654.
17. Zineh I., Beitelshes A.L., Gaedigk A., Walker J.R., et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. *Clin Pharmacol Ther*. 2004;76(6):536–44. PubMed PMID: 15592325.
18. Parvez B., Chopra N., Rowan S., Vaglio J.C., et al. A common beta1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. *J Am Coll Cardiol*. 2012;59(1):49–56. PubMed PMID: 22192668.
19. Lymperopoulos A., Bathgate A. Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown. *Pharmacogenomics*. 2012;13(3):323–41. PubMed PMID: 22304582.
20. Huntgeburth M., La Rosee K., ten Freyhaus H., Bohm M., et al. The Arg389Gly beta1-adrenoceptor gene polymorphism influences the acute effects of beta-adrenoceptor blockade on contractility in the human heart. *Clin Res Cardiol*. 2011;100(8):641–7. PubMed PMID: 21311897.
21. Liu J., Liu Z.Q., Tan Z.R., Chen X.P., et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. *Clin Pharmacol Ther*. 2003;74(4):372–9. PubMed PMID: 14534524.
22. Malhotra N., Abunassar J., Wells G.A., McPherson R., et al. A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window. *Int J Cardiol*. 2015;197:318–25. PubMed PMID: 26151596.

23. Caudle K.E., Dunnenberger H.M., Freimuth R.R., Peterson J.F., et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). *Genet Med.* 2017;19(2):215–223. PubMed PMID: 27441996.
24. Royal Dutch Pharmacists Association (KNMP). Dutch Pharmacogenetics Working Group (DPWG). Pharmacogenetic Guidelines [Internet]. Netherlands. Carbamazepine [Cited July 2017]. Available from: <http://kennisbank.knmp.nl/> [Access is restricted to KNMP membership.]
25. Leckband S.G., Kelsoe J.R., Dunnenberger H.M., George A.L. Jr, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing. *Clinical pharmacology and therapeutics.* 2013;94(3):324–8. PubMed PMID: 23695185.
26. Yip V.L., Pirmohamed M. The HLA-A*31:01 allele: influence on carbamazepine treatment. *Pharmgenomics Pers Med.* 2017;10:29–38. PubMed PMID: 28203102.
27. PharmGKB [Internet]. Palo Alto (CA): Stanford University. Haplotype CYP2D6*6 [Cited 26 Sept 2016]. Available from: <http://www.pharmgkb.org/haplotype/PA165816581>
28. PharmGKB [Internet]. Palo Alto (CA): Stanford University. Haplotype CYP2D6*9 [Cited 26 Sept 2016]. Available from: <https://www.pharmgkb.org/haplotype/PA165948317>
29. PharmGKB [Internet]. Palo Alto (CA): Stanford University. Haplotype CYP2D6*10 [Cited 26 Sept 2016]. Available from: <http://www.pharmgkb.org/haplotype/PA165816582>
30. PharmGKB [Internet]. Palo Alto (CA): Stanford University. Haplotype CYP2D6*17 [Cited 26 Sept 2016]. Available from: <http://www.pharmgkb.org/haplotype/PA165816583>
31. PharmGKB [Internet]. Palo Alto (CA): Stanford University. Haplotype CYP2D6*29 [Cited 26 Sept 2016]. Available from: <https://www.pharmgkb.org/haplotype/PA165948318>
32. PharmGKB [Internet]. Palo Alto (CA): Stanford University. Haplotype CYP2D6*41 [Cited 26 Sept 2016]. Available from: <http://www.pharmgkb.org/haplotype/PA165816584>
33. Gaedigk A., Sangkuhl K., Whirl-Carrillo M., Klein T., et al. Prediction of CYP2D6 phenotype from genotype across world populations. *Genet Med.* 2017;19(1):69–76. PubMed PMID: 27388693.
34. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. *Pharmacogenomics.* 2002;3(2):229–43. PubMed PMID: 11972444.
35. A, L.L., M.E. Naranjo, F. Rodrigues-Soares, L.E.M. Penas, et al., *Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.* *Expert Opin Drug Metab Toxicol,* 2014. **10**(11): p. 1569-83.
36. Hicks J.K., Bishop J.R., Sangkuhl K., Muller D.J., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. *Clin Pharmacol Ther.* 2015;98(2):127–34. PubMed PMID: 25974703.

License

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.